Predict your next investment

Corporation
HEALTHCARE | Healthcare Plans
cigna.com

See what CB Insights has to offer

Investments

18

Portfolio Exits

9

Funds

3

Partners & Customers

10

About Cigna

Cigna (NYSE:CI) is a global health service and financial company that provides services for people to improve their health, well-being, and security. Through its operating subsidiaries, Cigna provides an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, and vision care benefits, as well as group life, accident, and disability insurance.

Cigna Headquarter Location

900 Cottage Grove Road

Bloomfield, Connecticut, 06002,

United States

800-226-6000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cigna

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Cigna in 3 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

P

Pharma Supply Chain

19 items

H

Health Plans & Benefits Management

698 items

Companies developing or offering digital platforms and services, including online insurance marketplaces, data analytics for claims adjustment, benefits administration, and payments systems, that help make private health insurance more affordable, navigable, or transparent.

Cigna Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cigna Rank

Research containing Cigna

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cigna in 4 CB Insights research briefs, most recently on Jun 1, 2021.

Latest Cigna News

Cigna : Regulation FD Disclosure - Form 8-K

Nov 29, 2021

11/29/2021 | 06:21am EST Message : Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2021 Cigna Corporation Delaware 001-38769 Registrant's telephone number, including area code: (860)226-6000 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [_]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [_]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [_]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Cigna Corporation ("Cigna" or the "Company") officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, Cigna officials expect to reaffirm projected full year 2021 consolidated adjusted income from operations on a per share basis of at least $20.35 per share, and projected growth of at least 10% in consolidated adjusted income from operations on a per share basis for full year 2022 year-over-year. Cigna previously discussed its full year 2021 and 2022 outlook in its press release and investor presentation dated November 4, 2021 and during the related investor conference call. The press release, presentation and the conference call transcript are available in the Investor Relations section of Cigna's website located at www.cigna.com. Forward-looking statements in these documents and the related call speak only as of the date they were made. Adjusted income (loss) from operations is a principal financial measure of profitability used by Cigna's management because it presents the underlying results of operations of Cigna's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income. Adjusted income from operations is defined as shareholders' net income (or income before taxes for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. Cigna's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. Management is not able to provide a reconciliation of adjusted income from operations to shareholders' net income (loss) on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond Cigna's control. As such, any associated estimate and its impact on shareholders' net income could vary materially. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such a filing. -2- CAUTIONARY STATEMENT FOR PURPOSES OF THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This Current Report on Form 8-K (the "Report"), and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations for 2021 and 2022 on a per share basis included in Item 7.01 of this Report; as well as statements concerning future financial or operating performance, including our ability to deliver affordable, predictable and simple solutions for our customers and clients, including in light of the challenges presented by the COVID-19 pandemic; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions, including the sale of our international life, accident and supplemental benefits business; and other statements regarding Cigna's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms. Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; the scale, scope and duration of the COVID-19 pandemic and its potential impact on our business, operating results, cash flows or financial condition; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations; risks related to strategic transactions and realization of the expected benefits of such transactions, including with respect to the sale of our international life, accident and supplemental benefits business, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits, investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, stock market or interest rate declines, risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; unfavorable industry, economic or political conditions; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.cigna.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law. -3- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cigna Corporation

Cigna Investments

18 Investments

Cigna has made 18 investments. Their latest investment was in Giddings Fruit as part of their Loan on March 3, 2020.

CBI Logo

Cigna Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/10/2020

Loan

Giddings Fruit

$90M

Yes

2

8/1/2018

Series E

MDLIVE

$50M

Yes

2

11/17/2017

Series C

Prognos

$20.5M

Yes

5

6/14/2017

Series C - II

Subscribe to see more

$99M

Subscribe to see more

10

8/5/2016

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/10/2020

8/1/2018

11/17/2017

6/14/2017

8/5/2016

Round

Loan

Series E

Series C

Series C - II

Grant

Company

Giddings Fruit

MDLIVE

Prognos

Subscribe to see more

Subscribe to see more

Amount

$90M

$50M

$20.5M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

5

10

10

Cigna Portfolio Exits

9 Portfolio Exits

Cigna has 9 portfolio exits. Their latest portfolio exit was Cigna - Life and A&H Businesses (Asia Pacific) on October 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/7/2021

Divestiture

$991

31

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

10/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Divestiture

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

31

10

10

10

10

Cigna Acquisitions

12 Acquisitions

Cigna acquired 12 companies. Their latest acquisition was Express Scripts on December 20, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/20/2018

$991

Acq - P2P

17

10/31/2018

Acquired

1

12/14/2017

Series D - II

$54M

Acquired

2

7/11/2017

Subscribe to see more

$99M

Subscribe to see more

10

1/26/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/20/2018

10/31/2018

12/14/2017

7/11/2017

1/26/2015

Investment Stage

Series D - II

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$54M

$99M

$99M

Note

Acq - P2P

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

17

1

2

10

10

Cigna Fund History

3 Fund Histories

Cigna has 3 funds, including Cigna Mezzanine Partners III LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/1992

Cigna Mezzanine Partners III LP

Mezzanine (Third-Party)

$450M

1

12/31/1989

Cigna Mezzanine Partners II LP

Subscribe to see more

$99M

10

12/31/1985

Cigna/Morgan Stanley Mezz. Partners LP

Subscribe to see more

$99M

10

Closing Date

12/31/1992

12/31/1989

12/31/1985

Fund

Cigna Mezzanine Partners III LP

Cigna Mezzanine Partners II LP

Cigna/Morgan Stanley Mezz. Partners LP

Fund Type

Mezzanine (Third-Party)

Subscribe to see more

Subscribe to see more

Status

Amount

$450M

$99M

$99M

Sources

1

10

10

Cigna Partners & Customers

10 Partners and customers

Cigna has 10 strategic partners and customers. Cigna recently partnered with Mary Washington Health Alliance on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/25/2021

Partner

Mary Washington Health Alliance

United States

Cigna and Mary Washington Health Alliance Reach Agreement.

FREDERICKSBURG -- October 25 , 2021 -- Cigna Corporation and Mary Washington Health Alliance have reached a multi-year agreement that ensures Cigna Corporation customers will have access to Mary Washington Health Alliance 's hospitals , facilities and physician network for quality care .

1

10/20/2021

Supplier

Iora Primary Care

United States

12:00 ET Cigna Adds Iora Primary Care to Medicare Advantage Network in Phoenix Area

`` As Cigna Corporation continues to expand its Medicare Advantage network we are building partnerships with providers that share our focus on delivering affordable , high-quality care , '' said Dan Hoemke , president of Cigna Corporation 's Medicare Advantage business in Arizona .

3

10/18/2021

Partner

Medicare

United States

Cigna Offering Medicare Advantage In The St. Louis Area

Cigna Corporation contracts with Medicare Advantage to offer Medicare Advantage and PPO plans and Part D Prescription Drug Plans in select states , and with select State Medicaid programs .

6

9/20/2021

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

9/13/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/25/2021

10/20/2021

10/18/2021

9/20/2021

9/13/2021

Type

Partner

Supplier

Partner

Vendor

Partner

Business Partner

Mary Washington Health Alliance

Iora Primary Care

Medicare

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Cigna and Mary Washington Health Alliance Reach Agreement.

FREDERICKSBURG -- October 25 , 2021 -- Cigna Corporation and Mary Washington Health Alliance have reached a multi-year agreement that ensures Cigna Corporation customers will have access to Mary Washington Health Alliance 's hospitals , facilities and physician network for quality care .

12:00 ET Cigna Adds Iora Primary Care to Medicare Advantage Network in Phoenix Area

`` As Cigna Corporation continues to expand its Medicare Advantage network we are building partnerships with providers that share our focus on delivering affordable , high-quality care , '' said Dan Hoemke , president of Cigna Corporation 's Medicare Advantage business in Arizona .

Cigna Offering Medicare Advantage In The St. Louis Area

Cigna Corporation contracts with Medicare Advantage to offer Medicare Advantage and PPO plans and Part D Prescription Drug Plans in select states , and with select State Medicaid programs .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

3

6

10

10

Cigna Team

65 Team Members

Cigna has 65 team members, including current Chief Executive Officer, David Cordani.

Name

Work History

Title

Status

Daniel T. Pickett III

Zones, Hudson River Capital, and KeyCorp

Founder

Current

David Cordani

Chief Executive Officer

Current

Wendy Sherry

President

Current

Noelle Eder

Chief Information Officer

Current

Mark Boxer

Executive Vice President

Current

Name

Daniel T. Pickett III

David Cordani

Wendy Sherry

Noelle Eder

Mark Boxer

Work History

Zones, Hudson River Capital, and KeyCorp

Title

Founder

Chief Executive Officer

President

Chief Information Officer

Executive Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.